复宏汉霖(02696)：重组抗VEGF人源化单克隆抗体注射液HLX04-O用于湿性年龄相关性黄斑变性治疗的国际多中心3期临床研究达到主要研究终点

智通财经06-16

智通财经APP讯，复宏汉霖(02696)发布公告，近日，重组抗VEGF人源化单克隆抗体注射液HLX04-O(HLX04-O)在一项于湿性年龄相关性黄斑变性 (wet age-related macular degeneration, wAMD)患者中开展的国际多中心3期临床研究达到主要研究终点。本研究为一项国际多中心、随机、双盲、阳性对照的非劣效3期临床研究，旨在比较HLX04-O与雷珠单抗玻璃...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2643073041?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-16 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643073041","market":"sh","top_or_hot":-1,"title":"复宏汉霖(02696)：重组抗VEGF人源化单克隆抗体注射液HLX04-O用于湿性年龄相关性黄斑变性治疗的国际多中心3期临床研究达到主要研究终点","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，重组抗VEGF人源化单克隆抗体注射液HLX04-O(HLX04-O)在一项于湿性年龄相关性黄斑变性 (wet age-related macular degeneration, wAMD)患者中开展的国际多中心3期临床研究达到主要研究终点。本研究为一项国际多中心、随机、双盲、阳性对照的非劣效3期临床研究，旨在比较HLX04-O与雷珠单抗玻璃...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1454957.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696)：重组抗VEGF人源化单克隆抗体注射液HLX04-O用于湿性年龄相关性黄斑变性治疗的国际多中心3期临床研究达到主要研究终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696)：重组抗VEGF人源化单克隆抗体注射液HLX04-O用于湿性年龄相关性黄斑变性治疗的国际多中心3期临床研究达到主要研究终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 17:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1454957.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，重组抗VEGF人源化单克隆抗体注射液HLX04-O(HLX04-O)在一项于湿性年龄相关性黄斑变性 (wet age-related macular degeneration, wAMD)患者中开展的国际多中心3期临床研究达到主要研究终点。本研究为一项国际多中心、随机、双盲、阳性对照的非劣效3期临床研究，旨在比较HLX04-O与雷珠单抗玻璃...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1454957.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1454957.html","article_id":"2643073041","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643073041","pubTimestamp":1781600612,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复宏汉霖 发布公告，近日，重组抗VEGF人源化单克隆抗体注射液HLX04-O在一项于湿性年龄相关性黄斑变性 患者中开展的国际多中心3期临床研究达到主要研究终点。此外，HLX04-O与雷珠单抗在湿性年龄相关性黄斑变性 患者人群中整体、眼部、非眼部的安全性特征均相似，且安全性良好。2025年8月，HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","02696":"复宏汉霖","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC"},"translate_title":"Henlius (02696): The international multicenter phase 3 clinical study of recombinant anti-VEGF humanized monoclonal antibody injection HLX04-O for the treatment of wet age-related macular degeneration reached the primary study endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5},"content_text":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，重组抗VEGF人源化单克隆抗体注射液HLX04-O(HLX04-O)在一项于湿性年龄相关性黄斑变性 (wet age-related macular degeneration, wAMD)患者中开展的国际多中心3期临床研究达到主要研究终点。本研究为一项国际多中心、随机、双盲、阳性对照的非劣效3期临床研究，旨在比较HLX04-O与雷珠单抗玻璃体内注射(IVT)给药在湿性年龄相关性黄斑变性(wAMD)患者中的有效性和安全性。入组患者按照1:1的比例随机接受 HLX04-O(1.25 mg)或雷珠单抗(0.5 mg)IVT给药，每四周一次，在患者未发生死亡、撤回知情同意、失访或申办方终止研究的情况下，持续治疗一年。本次研究的主要研究终点为第36周最佳矫正视力(BCVA)较基线的平均变化，关键次要终点为第48周BCVA较基线的平均变化，次要研究终点为其他有效性、安全性、耐受性及药代动力学指标。研究结果显示，HLX04-O组第36周和第48周BCVA较基线的平均变化均非劣于雷珠单抗组，达到主要和关键次要研究终点。此外，HLX04-O与雷珠单抗在湿性年龄相关性黄斑变性 (wAMD)患者人群中整体、眼部、非眼部的安全性特征均相似，且安全性良好。HLX04-O是在本公司自主研发的汉贝泰®(贝伐珠单抗注射液)的基础上，根据眼科用药的需求对汉贝泰®(贝伐珠单抗注射液)的处方、规格和生产工艺进行优化，保持活性成分不变，而开发的新的眼科制剂产品，拟用于湿性年龄相关性黄斑变性(wAMD)的治疗。2023年7月，HLX04-O在一项于湿性年龄相关性黄斑变性(wAMD)患者中开展的1/2期临床研究结果显示其安全性及耐受性良好，并展现出初步疗效。2025年4月，HLX04-O在一项于湿性年龄相关性黄斑变性(wAMD)中国患者中开展的3期临床研究达到主要研究终点。 2025年8月，HLX04-O用于治疗湿性年龄相关性黄斑变性(wAMD)的上市注册申请(NDA)获国家药品监督管理局(NMPA)药品审评中心受理。根据IQVIA MIDASTM的最新数据(由IQVIA提供，IQVIA是全球医药健康产业专业信息和战略咨询服务提供商)，2025年，于全球范围内上市用于治疗湿性年龄相关性黄斑变性(wAMD)适应症的药物的销售额约为133.15亿美元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643073041","isCrawlerRequest":true}